• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to inhibiting pathway closure and thus reducing the transdermal flux of the formulation. In particular, the present invention contemplates at least one anti-healing drug effective in inhibiting a decrease in the transdermal flux of the drug compared to delivering or sampling the drug under substantially the same conditions except that the drug is free of anti-healing drugs. A method of inhibiting transdermal flux reduction of a drug that is transdermally delivered or sampled at a delayed time, including delivery or co-sampling.
    公开号:KR20030074595A
    申请号:KR10-2003-7003472
    申请日:2001-09-06
    公开日:2003-09-19
    发明作者:린웨이퀴；코르미어미쉘제이.엔.；대드도나피터이.；존슨쥬아니타에이.；매트리아노제임스에이.
    申请人:알자 코포레이션；
    IPC主号:
    专利说明:

    Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure}
    [2] Drugs are usually delivered orally or by injection. Unfortunately, many drugs are completely ineffective or have radically reduced efficacy when delivered orally, because they do not have the desired activity by being absorbed or adversely affected before entering the bloodstream. On the other hand, injecting the drug directly into the blood while ensuring no change in the drug upon delivery is difficult, not easy and inconvenient, and sometimes leads to poor patient compliance. Percutaneous drug delivery provides an improvement in this site. In many cases, however, the rate of delivery or influx of the agent via passive transdermal flux is limited and not therapeutically effective.
    [3] The method of increasing the transdermal flux of the formulation depends on the application of a current through the body surface, referred to as "electrotransport". "Electrotransportation" usually refers to the movement of beneficial agents, such as drugs or drug prodrugs, induced or enhanced by the application of dislocations through the body surface, such as skin, mucous membranes, nails and the like. The transport of the drug through the body surface can be carried out in a variety of ways. Ion osmotherapy, a widely used electrotransportation method, involves the transport of electrically induced charged ions. Another type of electrotransmission, electroosmotic, involves the transfer of solvents, including drugs, through the membrane under the influence of electric fields. Another type of electrotransportation, electroporation, involves the movement of a formulation through a hole formed by applying high voltage (s) to the membrane. In many cases, one or more of these methods may exist simultaneously in different ranges. Thus, the term "electrotransport" herein is to be interpreted as broadly as possible and electrically induced or enhanced transport of at least one charged or non-charged agent, or mixtures thereof, regardless of the particular mechanism or mechanism by which the agent is actually transported. It is given to include. Electrotransport delivery usually increases the influx of agents during percutaneous delivery.
    [4] Another way to increase formulation influx involves ice preserving or delivering the skin with a beneficial formulation, a skin penetration enhancer. In the case of delivery of the preparation through the skin, penetration enhancers, for example, increase the permeability and / or permeability of the body surface, form a hydrophilic pathway through the body surface and / or reduce the degradation of the preparation during transport and thereby influx thereof. Promote This method is typically used when the drug is delivered transdermally by passive diffusion.
    [5] Several attempts have also been made to mechanically penetrate or crush the skin to enhance the transdermal flux. Some of the earliest attempts to enhance transdermal flux include abrasion (eg, using sandpaper) or tape-striping the skin to destroy the stratum corneum. More recently, attempts have been made to puncture or cut the stratum corneum using very small puncture / cut devices. See, eg, U. S. Patent Nos. 5,879,326 (Godshall, et al.), 3,814,097 (Ganderton, et al.), 5,279,544 (Gross, et al.), 5,250,023 (Lee, et al.), 3,964,482 (Gerste, et al.), Reissue 25,637 (Kravitz, et al.) et al.), and PCT Publication Nos. WO 96/37155, WO 96/37256, WO 96/17648, WO 97/03718, WO 98/11937, WO 98/00193, WO 97/48440, WO 97/48441, WO 97/48442, WO 98/00193, WO 99/64580, WO 98/28037, WO 98/29298 and WO 98/29365. These devices use puncturing devices of various shapes and sizes to puncture the outermost layers of skin (ie, the stratum corneum). The drilling tools described in these references extend vertically from thin, flat membranes such as pads or sheets, for example. Some of these perforation tools or microprojections are extremely small, with sizes of only about 25-400 m (ie, length and width) and only about 5-50 litres of microprojection thickness. These tiny puncture / cut devices form corresponding small microslits / microcuts in the stratum corneum to enhance transdermal formulation delivery through them.
    [6] For human skin, it has been found that the pathway formed by microslit / microcuts is quickly closed and enclosed by the skin's natural healing process. Although this process is not fully understood at present, it is thought to be closely related to wound healing. Wound healing is a complex phenomenon involving a number of biological processes. The initial event, which takes several minutes during the wound healing process, is fibrin clot formation. In addition, many proinflammation mediators are released or formed in the early stages of wound healing. Vitrification of these factors leads to the migration of keratinocytes, leukocyte infiltration, fibroblast proliferation, leading to proteolysis, protein synthesis and tissue remodeling. Finally, the skin membrane is reshaped. In some cases, the increase in transdermal flux provided by these pathways is completely eliminated within hours of making the pathway. Thus, in the case of delivery microporation devices, the natural healing process of the skin can be prevented or at least delayed in order to percutaneously flux the preparation through the microcut / microslit over a delayed time period (e.g., 1 hour or more). Is required for the method.
    [7] The present invention fulfills these and related needs.
    [8] The present invention relates to a method for inhibiting transdermal flux reduction of a drug that is transdermally delivered or sampled over a delayed time, wherein the transdermal flux includes at least the destruction of the stratum corneum. Specifically, it has been found that co-delivery or co-sampling of drugs in the presence of anti-healing drugs can inhibit path closure of the skin formed as a result of skin stratum corneum destruction, thereby inhibiting transdermal flux reduction of the drug.
    [9] Thus, in a first aspect, the present invention provides that except that delivery delivers at least the stratum corneum of the skin (eg, by perforation) to form a plurality of pathways through which the drug passes, and the drug is free of anti-healing drugs. Percutaneous over a delayed time, comprising co-delivery or co-sampling with an amount of at least one anti-healing drug effective to inhibit a decrease in the transdermal flux of the drug compared to delivering or sampling the drug under substantially the same conditions A method of inhibiting transdermal flux reduction of a drug that is delivered or sampled.
    [10] In a second aspect, the present invention
    [11] (Iii) form a plurality of micro-breaks through the stratum corneum of the skin to form a pathway for the drug to pass through;
    [12] (Ii) reducing the drug transdermal flux as compared to delivering the drug under substantially the same conditions, except that there is no anti-healing drug (s) in the drug delivery relationship with the micro-destruction formed in step (iii). Localizing a reservoir comprising an amount of at least one anti-healing drug effective to inhibit:
    [13] It relates to a method for transdermal delivery of a drug over a delayed time comprising a.
    [14] In a third aspect, the present invention
    [15] (Iii) form a plurality of micro-breaks through the stratum corneum of the skin to form a pathway for the drug to pass through;
    [16] (Ii) reducing the drug transdermal flux as compared to delivering the drug under substantially the same conditions, except that there is no anti-healing drug (s) in the drug delivery relationship with the micro-destruction formed in step (iii). Localizing a reservoir comprising an amount of at least one anti-healing drug effective to inhibit:
    [17] It relates to a method for transdermal sampling a drug over a delayed time comprising a.
    [18] In this method, at least one skin stratum corneum is perforated, cut or otherwise destroyed (e.g., by friction or tape stripping) and most preferably at least the skin stratum corneum penetrates the skin keratin, allowing the drug and the anti-healing drug to pass through. It is perforated with a skin puncture apparatus having a plurality of mesh projections forming a plurality of paths. Anti-healing drug (s) may be administered before drug delivery or sampling; Or before and during the transdermal flux of the drug; Or in the transdermal flux of the drug; Or during and after transdermal flux of the drug.
    [19] In the method, preferably, the anti-healing drug (s) is an effective amount to produce an osmotic pressure greater than about 2000 kilopascals, preferably greater than about 3000 kilopascals, at 20 ° C. in anticoagulant, anti-inflammatory, cell migration inhibitor, and solution. Osmotic agents, and mixtures thereof.
    [20] Preferably, the anticoagulant is selected from the group consisting of heparin, pentosan polysulfate, citric acid, citrate salts, EDTA, and dextran, aspirin and liafolate sodium having a molecular weight of 2000 to 10,000 daltons. do.
    [21] Preferably the anti-inflammatory agent is selected from the group consisting of hydrocortisone sodium phosphate, betamethasone sodium phosphate, and triamcinolone sodium phosphate.
    [22] Preferably the drug that inhibits cell migration is selected from the group consisting of laminin and related peptides.
    [23] Preferably the osmotic agent is a zwitterionic compound such as glycine at a concentration high enough to produce an osmotic pressure of greater than about 2000 kilopascals, preferably greater than about 3000 kilopascals, in a biocompatible salt or solution such as sodium chloride.
    [24] Preferably, the drug to be transdermally delivered is a macromolecular drug selected from the group consisting of polypeptides, proteins, oligonucleotides, nucleic acids and polysaccharides.
    [25] Preferably, the polypeptide and protein are desmopressin, luteinizing hormone releasing hormone (LHRH) and LHRH analogues (e.g., goserelin, leuprolide, buserelin, tryptorelin), PTH, calcitonin , Interferon-α, interferon-β, interferon-γ, follicle stimulating hormone (FSH), hGH, insulin, insulinotropin, and ethtropoietin.
    [26] Preferably, the oligonucleotide is selected from the group consisting of ISIS2302, ISIS15839 and other phosphorothiolated oligonucleotides and other methoxyethylphosphorothioated oligonucleotides and the polysaccharide has a low molecular weight of 3000 to 12,000 Daltons. Molecular weight heparin and pentosan polysulfate.
    [27] Preferably, the drug to be transdermally sampled is a somatic sample. Preferably, the analytical sample is glucose.
    [28] Preferably, the drug and anti-healing drug (s) are delivered transdermally by manual diffusion and / or electrotransportation.
    [29] In a fourth aspect, the present invention
    [30] (Iii) an element having a plurality of skin perforation microprojections for forming a plurality of microcuts through the stratum corneum of the skin to form a path for the drug to pass through;
    [31] (Ii) a reservoir comprising an amount of at least one anti-healing drug effective to inhibit a decrease in drug transdermal flux as compared to sampling the drug under substantially the same conditions except that there is no anti-healing drug:
    [32] It relates to a device for transdermal delivery of a drug over a delayed time comprising a.
    [33] In a fifth aspect, the present invention
    [34] (Iii) an element having a plurality of skin perforation microprojections for forming a plurality of microcuts through the stratum corneum of the skin to form a path for the drug to pass through;
    [35] (Ii) a reservoir comprising an amount of at least one anti-healing drug effective to inhibit a decrease in drug transdermal flux as compared to sampling the drug under substantially the same conditions except that there is no anti-healing drug:
    [36] It relates to an apparatus for transdermal sampling a drug over a delayed time comprising a.
    [37] In a sixth aspect, the present invention
    [38] (Iii) an element having a plurality of skin perforation microprojections for forming a plurality of microcuts through the stratum corneum of the skin to form a path for the drug to pass through;
    [39] (Ii) a reservoir comprising an amount of at least one anti-healing drug effective to inhibit a decrease in drug transdermal flux as compared to sampling the drug under substantially the same conditions except that there is no anti-healing drug:
    [40] It relates to a kit for transdermal delivery or sampling of a drug over a delayed time comprising a.
    [41] Preferably, the anti-healing drug (s) is an anticoagulant, anti-inflammatory agent, cell migration inhibitor, and an effective amount of osmotic agent that produces an osmotic pressure in solution of greater than about 2000 kilopascals, preferably greater than about 3000 kilopascals, at 20 ° C., And mixtures thereof.
    [42] Preferably, the anticoagulant is selected from the group consisting of heparin, pentosan polysulfate, citric acid, citrate salts, EDTA, and dextran, aspirin and liafolate sodium having a molecular weight of 2000 to 10,000 daltons. do.
    [43] Preferably the anti-inflammatory agent is selected from the group consisting of hydrocortisone sodium phosphate, betamethasone sodium phosphate, and triamcinolone sodium phosphate.
    [44] Preferably the drug that inhibits cell migration is selected from the group consisting of laminin and related peptides.
    [45] Preferably the osmotic agent is a zwitterionic compound such as glycine at a concentration high enough to produce an osmotic pressure of greater than about 2000 kilopascals, preferably greater than about 3000 kilopascals, in a biocompatible salt or solution such as sodium chloride.
    [46] Preferably, the drug to be transdermally delivered is a macromolecular drug selected from the group consisting of polypeptides, proteins, oligonucleotides, nucleic acids and polysaccharides.
    [47] Preferably, the polypeptide and protein are desmopressin, luteinizing hormone releasing hormone (LHRH) and LHRH analogues (e.g., goserelin, leuprolide, buserelin, tryptorelin), PTH, calcitonin , Interferon-α, interferon-β, interferon-γ, follicle stimulating hormone (FSH), hGH, insulin, insulinotropin, and ethtropoietin.
    [48] Preferably, the oligonucleotide is selected from the group consisting of ISIS2302, ISIS15839 and other phosphorothiolated oligonucleotides and other methoxyethylphosphorothioated oligonucleotides and the polysaccharide has a low molecular weight of 3000 to 12,000 Daltons. Molecular weight heparin and pentosan polysulfate.
    [49] Preferably, the drug to be transdermally sampled is a somatic sample. Preferably, the analytical sample is glucose.
    [1] The present invention relates to inhibiting pathway closure and thus reducing the transdermal flux of the formulation. In particular, the present invention contemplates at least one anti-healing drug effective in inhibiting a decrease in the transdermal flux of the drug compared to delivering or sampling the drug under substantially the same conditions except that the drug is free of anti-healing drugs. A method of inhibiting transdermal flux reduction of a drug that is transdermally delivered or sampled at a delayed time, including delivery or co-sampling.
    [50] The present invention is described in more detail with reference to the accompanying drawings, wherein;
    [51] 1 is a graph of the effect of pathway closure inhibitors on passive percutaneous pentosan polysulfate influx.
    [52] 2 is a graph of the effect of pathway closure inhibitors on passive percutaneous pentosan polysulfate delivery.
    [53] 3 is a graph of the effect of pathway obstruction inhibitors on passive percutaneous pentosan polysulfate influx.
    [54] 4 is a graph of the effect of pathway closure inhibitors on passive percutaneous pentosan polysulfate delivery.
    [55] 5 is a graph of the effect of pathway closure inhibitors on passive percutaneous pentosan polysulfate delivery.
    [56] 6 is a graph of the effect of pathway closure inhibitors on passive percutaneous pentosan polysulfate delivery.
    [57] 7 is a graph of the effect of pathway closure inhibitors on passive percutaneous DNA delivery.
    [58] 8 is a schematic side view of an apparatus for transdermal delivery or sampling of a drug according to the present invention.
    [59] Justice:
    [60] Unless otherwise stated, the terms used in the present application have the following meanings.
    [61] The term "percutaneous influx" refers to the rate of passage of any drug into or through an individual's skin or the rate of passage of an analyte through an individual's skin.
    [62] The term "transdermal" means delivery or extraction of a drug through the skin.
    [63] The term "path" means a passageway formed in the stratum corneum of the skin that is agitated to increase the transdermal influx of the drug. Keratin of the skin can be disturbed by well known methods such as wiping with sandpaper, peeling off tapes, forming micro cuts, and the like. Other methods are described in US Pat. Nos. 6,022,316, 5,885,211 and 5,722,397, which are incorporated herein in their entirety. Preferably the passageway is formed of a device having a plurality of keratin-piercing microprojections to generate microcuts in the keratin by disturbing the skin.
    [64] As used herein, the term “microprojection” refers to a very small keratin piercing element, typically having a length of less than 500 micrometers, preferably less than 250 micrometers, which allows keratin transmission. In order to penetrate the keratin, the microprojections preferably have a length of at least 50 micrometers. The microprojections may be formed in different shapes, such as needles, hollow needles, knives, pins, punches, and combinations thereof.
    [65] The term "microprojection array" as used herein refers to a plurality of microprojections arranged in an array for piercing of keratin. The microprojection array forms a plurality of blades from a thin sheet and overlaps each blade from the plane of the sheet to form the configuration shown in FIG. The microprojection array may be formed by other known methods, such as connecting a plurality of strips with microprojections along the edge of each strip. The microprojection may comprise an empty needle for injecting the liquid formulation. Examples of microprojection arrays include U.S. Patent No. 5,879,326 to Godshall et al., 3,814,097 to Ganderton et al., 5,279,544 to Gross et al., 5,250,023 to Lee et al., 3,964,482 to Gerstel et al., 25,637 to Kravitz et al., And PCT. Publication Nos. WO 96/37155, WO 96/37256, WO 96/17648, WO 97/03718, WO 98/11937, WO 98/00193, WO 97/48440, WO 97/48441, WO 97/48442, WO 98 / 00193, WO 99/64580, WO 98/28037, WO 98/29298, and WO 98/29365, all of which are incorporated herein by reference in their entirety.
    [66] As used herein, the term "extended delivery" means a delivery time of at least 30 minutes, preferably from several hours to about 24 hours, more preferably between about 8 and 24 hours.
    [67] As used herein, the term "simultaneous-delivery" means before the drug is delivered; Before and during transdermal influx of drugs; During transdermal influx of drugs; And / or anti-wound therapeutic agents are delivered percutaneously during and after percutaneous influx of drugs.
    [68] As used herein, the term "simultaneous-sampling" means that the drug is sampled by transdermal influx; Before and during transdermal influx of drugs; During transdermal influx of drugs; And / or anti-wound therapeutic agents are delivered percutaneously during and after percutaneous influx of drugs.
    [69] For the purpose of percutaneous delivery, the term "drug" as used herein refers to a drug, medicament, compound, composition or mixture thereof having a pharmacological effect, often a useful effect. It is the broadest range, such as pharmacologically acceptable substances that can be delivered to life to produce the desired effect, usually a useful effect. Generally, this includes anti-infective agents such as antibiotic antiviral agents; Analgesics such as fentanyl, sulfentaryl, and bupronorphine, and analgesic combinations; anesthetic; Loss of appetite; Anti-arthritis agents; Anti-asthmatic agents such as terbutalin; Antiepileptics; Antidepressants; Antidiabetic agents; Antidiarrheal; Antihistamines; Anti-inflammatory agents; Anti-headaches; Anti-sickness agents such as scopolamine and ontansetron; Anti-nausea agents; Antitumor agents; antiparkinson's drugs; Antipruritic agents; Antipsychotics; fever remedy; Anticonvulsants, including the gastrointestinal tract and urinary tract; Anticholinergic; Sympathetic nervous system; Antitank derivatives; Cardiovascular preparations including calcium channel blockers such as nifedipine; Beta agonists such as dobutamine and lithodrin; ACE inhibitors such as ranitidine, diuretics; Vasodilators including systemic, coronary, peripheral and brain; Central nervous stimulant; Cough and cold preparations; Decongestants; Diagnostic agents; Hormones such as parathyroid hormones; sleeping pills; Immunosuppressants; Muscle relaxants; Parasympathetic stimulation blockers; Parasympathetic nervous system; Prostaglandins; protein; Peptides; stimulant; Includes, but is not limited to, therapeutics used in all major therapeutic fields such as vaccines, sedatives and stabilizers.
    [70] The present invention is useful for controlled delivery of macromolecules that are difficult to transdermally deliver due to peptides, polypeptides, proteins or other sizes. These macromolecular materials typically have a molecular weight in the range of at least about 300 Daltons, more typically in the range of about 300 to 40,000 Daltons. Examples of polypeptides and proteins delivered according to the present invention include, but are not limited to, LHRH, LH high analogs (such as goserelin, leuprolide, buserelin, tryptorelin, gonadorelin, napapelin and leuprolide). , GHRH, GHRF, insulin, insulinnotropin, calcitonin, octreotide, endorphin, TRH, NT-36 (chemical name: N-[[(s) -4-oxo-2-azetidinyl] -carbonyl] Growth factors such as -L-histidyl-L-prolinamide), ripressin, pituitary hormones (ie, HGH, HMG, HCG, desmopressin acetate, etc.), progesterone, α-ANF, exporter GFRF), P-MSH, GH, somatostatin, bradykinin, somatotropin, platelet-derived growth factor, asparaginase, bleomycin sulfate, chemopapine, cholecystokinin, chorionic gonadotropin, corticotropin (ACTH) , Erythropoietin, epoprostenol (platelet aggregation inhibitor), glucagon, hirudin and hirlog Dean analogs, hyaluronidase, interleukin-2, sex hormones (uropolytropin (FSH) and LH), oxytocin, streptokinase, tissue plasminogen activators, urokinase, vasopressin, desmopressin, ACTH analogs, ANP, ANP clearance inhibitors, angiotensin II antagonists, antidiuretic hormone agonists, antidiuretic hormone antagonists, bradykinin antagonists, CD4, seredase, CSI's, enkephalins, FAB fragments, IgE peptide inhibitors, IGF-1, neuronal factor, colony Stimulating factors, parathyroid hormones and agonists, parathyroid hormone antagonists, prostaglandin antagonists, pentagetide, protein C, protein S, renin inhibitors, thymosin a-1, thrombolytics, TNF, PTH, 3000 to 12,000 daltons Heparin, vaccine, vasopressin antagonist analogs with molecular weight, interferon-α, -β and -gamma, alpha-1 antitrypsin (recombinant) TGF-β.
    [71] One or more drugs may be included in the drug formulation in the methods of the invention, and the use of the term “drug” is not intended to exclude two or more drugs or drugs.
    [72] The drug may include various forms such as free base, acid, charged or uncharged molecule, component of a molecular complex or non-irritating, pharmacologically acceptable salt. In addition, simple derivatives (ethers, esters, amides, and the like) of drugs which are easily hydrolyzed by the body's pH, enzymes and the like can also be used. The drug may be in the form of a solution, suspension or a combination thereof within the drug reservoir. Alternatively, the drug may be particulate.
    [73] The amount of drug used in the delivery device is the amount required to deliver a therapeutically useful amount of drug to achieve the desired result. In practice, this varies very widely depending on the particular drug, the site of delivery, the severity of the disease, and the desired drug effect. Therefore, it is not practical to define specific ranges for the pharmacologically useful amounts of the inclusions included in the method. For the purpose of percutaneous sampling, the term "drug" as used herein refers to the analyte to be sampled in the body. As used herein, the term “analyte” refers to a chemical or biological substance or compound suitable for passage through a biological membrane by the techniques taught herein, or by techniques known in the art, each individual in Wants to know the concentration and activity of that substance. Glucose is a specific example of the analyte because glucose is a sugar suitable for skin penetration, for example an individual with diabetes wants to know its blood glucose level. Other examples of analytes include, but are not limited to, sodium, potassium, bilirubin, urea, ammonia, calcium, lead, iron, lithium, salicylates, alcohols, legal substances, illegal drugs, and the like.
    [74] The term “therapeutic” amount or rate refers to the amount or rate of drug necessary to elicit the desired pharmacological effect, often a useful effect.
    [75] The term "passive" transdermal delivery describes, in the present specification, the passage of a drug by passive conviction, for example through a body surface such as the skin. Typically passive delivery devices have drug reservoirs containing high concentrations of drugs. The device is left in contact with the body surface for an extended period of time and allows diffusion from the reservoir into the patient's body, which has a much lower concentration of drug. The primary driving force for passive drug delivery is the concentration gradient of drug through the skin. In this type of delivery, the drug reaches the blood by diffusion through the body's dermal layer. Preferred drugs for manual delivery are hydrophobic nonionics because they must pass through the fat layer of the skin.
    [76] As used herein, the term "electrotransport" refers to a drug or prodrug, such as through a body surface or membrane, such as the skin, mucous membranes, or nails, at least partially induced by applying an electric field through the body surface (eg skin). Describe the passage of matter. The widely used electrotransportation process, iontophoresis, involves the electrically induced transport of therapeutic agents in the form of charged ions. Ionizable therapeutic agents, such as salt forms that become charged ions when dissolved, are preferred for iontophoresis delivery because charged ions migrate by electrophoresis within the applied electric field. Other types of electroosmotic, electrotransportation processes involve liquids containing charged and / or uncharged therapeutic agents dissolved therein that migrate through biological membranes (eg skin) under the influence of an electric field. Another type of electrophoresis, electrophoresis, involves the application of high voltage pulses to a biobiological membrane to form a temporary membrane and thereby deliver a therapeutic drug. However, in any electrotransportation process, one or more of these methods may occur to some degree simultaneously. Thus, as used herein, the term "electrotransport" refers to the electrical nature of at least one drug in charged, ie ionic, non-charged, or mixed form thereof, regardless of the particular mechanism in which the drug is actually transported. It is construed to the widest extent possible, including induced or enhanced transport.
    [77] The term “anti-wound recovery agent”, alone or in combination, means a substance that prevents or reduces the natural wound healing process of the skin and thereby prevents blockade of pathways formed by disturbances such as microslits / microcutions in the skin keratin. . Suitable anti-wound healing agents include, but are not limited to:
    [78] (1) An osmotic agent comprising natural compounds such as glucose, salts such as sodium chloride, and zwitterionic compounds such as amino acids.
    [79] The formulations (including those reconstituted from the dry formulations) should have an osmotic pressure at 20 ° C. of at least about 2000 kPa and more preferably at least about 3000 kPa. Osmotic pressure is calculated from the following relationship.
    [80] Π = iMRT
    [81] Where I is the Wanthoff factor, M is the molar concentration of the solute, R is the general gas constant (8.314 J K1 mol 1) and T is the Kelvin temperature.
    [82] For neutral compounds, I is 1 and the concentration at 2000 kPa is 0.8 M; And at about 3000 kPa the concentration is 1.2 M.
    [83] Neutral compounds include:
    [84] (a) an organic solvent such as dimethylsulfoxide.
    [85] (b) acids in neutral state, such as boric acid.
    [86] (c) a polymer of ether alcohol and ethylene oxide comprising at least one alcohol group and having a molecular weight ranging from 92 to 500. Compounds in this group include ethoxydiglycol, diethylene glycol, dipropylene glycol, triethylene glycol, PEG-4, PEG-6, PEG-8 and PEG-9, and the like;
    [87] (d) aliphatic alcohols having two alcohol groups such as propylene glycol, butane diol and the like;
    [88] (e) aliphatic having three alcohol groups such as glycerol and 1,2,6-hexanetriol;
    [89] (f) tetrahydric alcohols such as erythritol and trytol;
    [90] (g) pentahydric alcohols such as adonitol, xylitol, arabitol and the like;
    [91] (h) hexahydric alcohols such as sorbitol, mannitol, galactitol and the like;
    [92] (i) aliphatic compounds containing one ketone or aldehyde group and at least two alcohol groups. Compounds in this group include deoxyribose, ribulose, xylulose, sicose, sorbose and the like.
    [93] (j) cyclic polyols such as inositol and the like;
    [94] (k) Apios, arabinose, lyxose, ribose, xylose, digitoxose, fucose, quasitol, quinobose, lanose, allose, altose, fructose, garactose, glucose, gulose, hippo Monosaccharides such as melose, idose, mannose, tagatose and the like;
    [95] (l) disaccharides such as sucrose, trehalose, pirmeberos, bicyanos, lutinos, silaviose, cellobiose, genthiobis, lactose, lacculose, maltose, melibiose, sophorose, and turanose and the like.
    [96] For salts with i = 2, the salt concentration at about 2000 kPa is about 0.4 M; About 0.6 k at about 3000 kPa. These salts include: sodium chloride, acetic acid, propionic acid, glycolic acid, pyruvic acid, hydracrylic acid, lactic acid, pivalic acid, β-hydroxybutyric acid, glyceric acid, sorbic acid, mandelic acid, atrolic acid, Of tropic acid, quinic acid, glucuronic acid, gluconic acid, gulonic acid, glucoheptonic acid, benzyl acid, ammonia, monoethanolamine, diethanolamine, aminomethylpropanediol, tromethanemin, triethanolamine, galactosamine and glucosamine Salt form.
    [97] For salts with i = 3, the salt concentration at about 2000 kPa is about 0.3 M; About 0.4 M at about 3000 kPa. These salts include: salt forms of phosphoric acid, malonic acid, fumaric acid, maleic acid, succinic acid, trotronic acid, oxaloacetic acid, malic acid, alpha-ketoglutaric acid, citramal acid, and tartaric acid.
    [98] For salts with i = 4, the salt concentration at about 2000 kPa is about 0.2 M; About 0.3 M at about 3000 kPa. These salts include: salt forms of aconitic acid, citric acid and isocitric acid.
    [99] For zwitterionic compounds, I is about 1 and its concentration at about 2000 kPa is about 0.2 M; About 0.3 M at about 3000 kPa.
    [100] Zwitterionic compounds include: amino acids such as glycine, alanine, proline, threonine and valine, diamino acids such as glycylglycine, buffers such as 4-morpholine propane sulfonic acid (MOPS), (2-{[tris (Hydroxymethyl) methyl] amino} -1-ethane sulfonic acid (TES), 4- (2-hydroxyethyl) -1-piperazineethane sulfonic acid (HEPES), β-hydroxy-4- (2- Hydroxyethyl) -1-piperazinepropane sulfonic acid monohydrate (HEPPSO), tricin, bicine, CHES and CAPS and the like.
    [101] (2) anticoagulants such as citric acid, citrate salts (e.g. sodium citrate), dextran sulfate sodium, EDTA, pentosan polysulfate, oligonucleotides, aspirin, low molecular weight heparin and liafolate sodium.
    [102] (3) betamethasone 21-phosphate disodium salt, triamcinolone acetonide 21-disodium phosphate, hydrocortamate hydrochloric acid, hydrocortisone 21-phosphate disodium salt, methylprednisolone 21-phosphate disodium salt, methylprednisolone 21-succinate Sodium salt, paramethasone isodium phosphate, prednisolone 21-succinate sodium salt, prednisolone 21-m-sulfobenzoate sodium salt, prednisolone 21-diethylaminoacetate hydrochloric acid, prednisolone sodium phosphate, prednilidene 21-diethylaminoa Cetite hydrochloric acid, tyr-amcinolone acetonide 21-disodium phosphate; Aspirin and other salicylates, bromfenac, diclofenac, diflunisal, etodolak, phenofene, ibuprofen, indomethacin, ketoprofen, ketorac, meclofenamate, mefenacane, naproxen, oxaprozin Salt forms of NSAIDs, such as pyroxicam, sulindac, tolmetin; And anti-inflammatory peptides such as antiflavin 1 and antiflavin 2; And
    [103] (4) cell migration agents and related peptides such as laminin and fibronectin related peptides.
    [104] The concentration range of anticoagulant, anti-inflammatory and cell migration inhibitors is between 0.1 and 10% in the formulation.
    [105] Mode for carrying out the invention
    [106] The main barrier properties of the skin, such as drug diffusion resistance, are in the outermost layer of the skin, ie the stratum corneum. The inner part, ie the support layer of the epithelium, comprises three layers of granule layer, embryonic layer and germination layer. Absorption or transport of the drug through these layers is inherently little or no resistance. Therefore, to increase the percutaneous influx, the microprojections used to generate pathways to the body surface in accordance with the present invention only need to pass through the stratum corneum so that the drug is percutaneously delivered or sampled with little or no resistance through the skin. There is.
    [107] Numerous attempts have been made to generate pathways by mechanically penetrating or disturbing the skin to increase percutaneous influx.
    [108] However, the pathway caused by microslit / microcutting is quickly closed or blocked by the natural wound healing process of the skin. Thus, the improvement of the percutaneous drug influx provided by these pathways completely disappears within hours of pathogenesis. The present invention prevents the percutaneous influx of the drug from being reduced due to blockage of the pathway after pathway generation.
    [109] In one embodiment, the skin is treated with a microprojection array device to form small cuts, slits, or holes called paths in the outermost layer of the body surface to a limited depth. The microprojections may be formed in different forms such as needles, hollow needles, pins, punches, and combinations thereof. The drug delivery or sampling reservoir is positioned to contact the body surface area that has been pretreated to deliver or sample the drug. This drug delivery or sampling reservoir contains an anti-wound recovery co-delivery with the drug. This anti-wound remedy prevents or at least prevents the pathway from being blocked and thus inhibits the reduction of the percutaneous influx of drugs being delivered or sampled. Alternatively, the anti-wound depot reservoir and drug delivery or sampling reservoir may be different reservoirs.
    [110] FIG. 8 illustrates a delivery or sampling patch 10 comprising a plurality of microprojections 12, reservoir 14, an adhesive support layer 16, and an impermeable support layer 18. Although the reservoir 14 is illustrated on the far side of the microprojection 12, it should be understood that the reservoir may be located in other locations. For example, the reservoir 14 may be provided in a separate layer on the near or far side of the skin of the base sheet supporting the microprojection 12. The reservoir 14 may be provided with a coating on the microprojection and / or the reservoir may be provided with a coating on another portion of the patch 10. Although the present invention has been described as including a drug and an anti-wound recovery agent, it should be understood that the drug and anti-wound recovery agent may be provided in the same or different reservoirs within the device.
    [111] The device of the present invention can be used in connection with a delivery drug, a sampling drug, or both. In particular, the devices of the present invention are used in connection with percutaneous drug delivery, percutaneous analyte sampling, or both. Transdermal delivery devices for use in accordance with the present invention may include, but are not limited to passive devices, electrotransport devices, osmotic devices, and pressure-driven devices. Percutaneous sampling devices used in the present invention may include, but are not limited to, passive devices, reverse electrotransport devices, negative pressure driven devices, and osmotic devices. The transdermal device of the present invention can be used in combination with other methods for increasing drug inflow, such as skin permeation enhancers.
    [112] The following preparations and examples are provided to enable those skilled in the art to more clearly understand and to practice the present invention. It is not intended to be exhaustive or to limit the scope of the present invention.
    [113] Example 1
    [114] Three model drugs exhibiting different charge properties with a decrease in drug flux: pentosan polysulfate (PPS) (highly negative phonetic compound), DECAD (synthetic model decapeptide comprising two positives at pH 5.5), and inulin (Neutral polysaccharide). These compounds do not significantly penetrate the skin without the use of penetration enhancers of the skin membrane or without physical destruction.
    [115] In this test, PPS, DECAD, and inulin were delivered by manual diffusion through intradermal routes formed by pretreatment with microprojection arrays. Pretreatment involves placing the microprojection arrays on the skin with sufficient force to form a number of myscolets / microcuts through the stratum corneum. The microprojection array is then removed from the skin and then some formulation delivery device or formulation reservoir is sited via the route to effect formulation delivery or sampling. Pretreatment was used instead of the integrated system because path closure appears faster and more reproducible after pretreatment than when microprojections remain on the skin during drug delivery. The concentration of PPS was below the concentration required for anticoagulant efficacy. All drugs were dissolved in water and the solution gelled with 2% hydroxyethylcellulose. PPS, DECAD and inulin concentrations were 0.1 mg / mL, 13 mg / mL and 2.5 mg / mL, respectively. PPS and DECAD were radiolabeled with trinium. Insulin was radiolabeled at 14 C.
    [116] In alopecia guinea pigs (HGPs), one side of the skin was pulled on both sides when using the system. The use of microprojection arrays was performed with the impact applicator. System used is the stay Ness steel consists of a central 2cm 2 stores a foam double adhesive ring having a roll (diameter 3.8 cm, 0.16 cm thickness) of the containing fine projection array having an area of 2cm 2 and having a 0.025 mm thickness It consisted of a trapezoidal blade bent at an angle of about 90 ° to the sheet and sheet surface, and the length of the microprojections was 545 micrometers, and the density of the microprojections was 72 microprojections / cm 2 . After use, the stretching tension was released and the microprojection array was removed leaving the adhesive ring attached to the skin. The drug formulation (350 μL) was dispersed into the drug compartment and a backing membrane was used on the adhesive outer surface of the ring to seal the system. A total of six HGPs were treated with the same drug formulation. At 1 h and 24 h of drug use, the system was removed from the three HGPs in each group and the remaining drug was washed from the skin. Radioactivity of urine excretion was measured during these two days of patch removal to determine the amount of drug infiltrated during this time interval and corrected from post-injection excretion of Perceton (preliminary studies were post-injection for 3H-PPS, 3H DECAD, and 14C inulin). The percentage of emissions over two days was 32%, 65% and 94% respectively). The results (Table I) showed that between 1 hour and 24 hours the path formed by skin perforation by microprojections was at least partially closed, decreasing to at least first order magnitude for all drugs.
    [117] Table I
    [118] Flux of model drug after microprojection array pretreatment
    [119]
    [120] Example 2
    [121] Inhibition of pathway disruption by chemicals was studied for 24 hours after skin pretreatment with microprojection arrays and drug-containing formulations. The survey was performed by dye injection evaluation in the route.
    [122] In alopecia guinea pigs (HGPs), one side of the skin was pulled on both sides when using the system. The use of microprojection arrays was performed with the impact applicator. System used is the stay Ness steel consists of a central 2cm 2 stores a foam double adhesive ring having a roll (diameter 3.8 cm, 0.16 cm thickness) of the containing fine projection array having an area of 2cm 2 and having a 0.025 mm thickness It consisted of a trapezoidal blade bent at an angle of about 90 ° to the sheet and sheet surface, and the length of the microprojections was 545 micrometers, and the density of the microprojections was 72 microprojections / cm 2 . After use, the stretching tension was released and the microprojection array was removed leaving the adhesive ring attached to the skin. The formulation (350 μL) comprising the compound to be tested in water and optionally a gelling agent (2% hydroxyethylcellulose (HEC) or 50% silica gel) is dispersed in the drug reservoir and the support membrane is used on the adhesive outer surface of the ring. Was sealed. A second system containing different agents in guinea pigs was delivered to the opposite site. After 24 hours of use, the three systems in each group were removed and the remaining formulation removed from the skin. The skin was stained with 1% methylene blue solution. Excess dye was thoroughly removed with a 70% isopropyl alcohol pad and the site was photographed. Photos show scoring from 0 to 5, where 5 represents dye uptake obtained immediately after microprojection array use and 0 represents salt uptake 24 hours after contact with control formulation. A score of 0.5 or higher was judged to be significant. Various osmotic agents, anticoagulants, anti-inflammatory agents, binders and gels of different pH and various adhesives were tested (Table II). The most effective formulations of osmotic agents are polyol 1,2,6-hexanetriol glucuronic acid, polymers of ethylene oxide diethylene glycol, pentahydric alcohol adonitol, hexahydric alcohol sorbitol, polling-amine tromethamine And monosaccharide glucose. Of the anticoagulants, citric acid, EDTA, and dextran 5000 were the most effective agents for preventing pathway closure. Significant efficacy was shown with anti-inflammatory betamethasone disodium phosphate and ketoprofen sodium salt. Keralytic salicylic acid also had efficacy against pathway closure. Low pH also inhibited pathway closure. Non-irritating concentrations of surfactants (anions, cations and nonions) had no efficacy. Inert formulations did not prevent pathway closure. Sites exposed to glycerol and citric acid were stained with India ink to confirm that the pathway was open for larger size compounds.
    [123] Table II
    [124] Pathway Inhibition Inhibition by Chemicals Evaluated by Methylene Blue After Microprojection Array Pretreatment
    [125]
    [126]
    [127]
    [128]
    [129]
    [130] Example 3
    [131] Pentosan polysulfate (PPS), a highly-negative compound, does not significantly penetrate the skin without the use of skin membrane penetration enhancers or without physical destruction. In this test, PPS was delivered by passive diffusion through the intradermal pathway formed by the microprojection array. The concentration of PPS was below the concentration required for inhibition of pathway disruption (see Table II). Therefore, at the concentrations used in this test, PPS acted as a drug without activity for pathway closure. The pathway disruption inhibitors identified in Example 2 were also shown to improve drug flux through the skin in vivo.
    [132] In all guinea pigs, in alopecia guinea pigs (HGPs), one skin was pulled to both sides when using the system. The use of microprojection arrays was performed with the impact applicator. System used is the stay Ness steel consists of a central 2cm 2 stores a foam double adhesive ring having a roll (diameter 3.8 cm, 0.16 cm thickness) of the containing fine projection array having an area of 2cm 2 and having a 0.025 mm thickness It consisted of a trapezoidal blade bent at an angle of about 90 ° to the sheet and sheet surface, and the length of the microprojections was 545 micrometers, and the density of the microprojections was 72 microprojections / cm 2 . After use, the stretching tension was released and the microprojection array was removed leaving the adhesive ring attached to the skin. Hydrogels containing 3 H-PPS in water (0.1 mg / mL of PPS, 2% HEC, 350 μL) were dispersed into the drug compartment and the support membrane was used on the adhesive outer surface of the ring to seal the system. Additional groups of HGPs were treated in the same manner except the formulation included 3% trisodium citrate salt or 50% 1,2,6-hexanetriol. At 1 and 24 hours after use, three systems were removed from each group and the remaining drug was removed from the skin. Urine excretion of tritium was measured to determine the amount of drug infiltrated during this time interval (previous studies showed that 32% of tritium derived from 3 H-PPS injected intravenously in HGP was excreted from urine). As shown in FIG. 1, the results show that the flux decreased by about 12-fold between 1 and 24 hours, demonstrating that the pathway was closed. Citric acid and 1,2,6-hexanetriol inhibited this decrease. The flux in the presence of 1,2,6-hexanetriol was reduced by less than 2 times between 1 and 24 hours. As shown in FIG. 2, the total amount transported compared to the control increased about 4 and 7 times in the presence of citric acid and 1,2,6 hexanetriol, respectively.
    [133] Example 4
    [134] A second test was conducted using PPS. The conditions were the same as described in Example 3 except that the microprojection array had a shorter blade, 194 micrometers in length, and a denser microprojection density (190 microprojections / cm 2 ). The concentration of PPS was 0.16 mg / mL which was still below the concentration required for inhibiting pathway disruption. Evaluation was carried out at 45 minutes instead of 1 hour. In addition, an additional group of animals was delivered with a formulation comprising a 3% trisodium citrate salt and a 50% 1,2,6-hexanetriol mixture. Similar to the previous example, the results shown in FIG. 3 indicate that the flux decreased significantly between 0.75 and 24 h, which demonstrates path collapse. The additive used does not change the PPS flux at 45 minutes, which does not exhibit penetration enhancing properties and shows that the pathway does not close significantly during this period. The flux completely inhibited the decrease in PPS flux between 45 minutes and 24 h in the presence of 3% trisodium citrate salt and 50% 1,2,6-hexanetriol mixture. The total amount of PPS transported is shown in FIG. 4. The efficacy in the presence of 3% trisodium citrate salt and 50% 1,2,6hexanetriol was better in the additive. This may suggest that these two agents work against different wound healing mechanisms (citric acid prevents clot formation while 1,2,6-hexanetriol prevents another regeneration process such as keratinocyte migration). can do).
    [135] Example 5
    [136] Further tests were run using PPS. The conditions were the same as described in Example 4 except the sodium gluconate salt, glucuronic acid sodium salt and glucose were evaluated at a concentration of 0.6 M with or without 3% citric acid. Similar to the previous example, as shown in FIG. 5, the results indicate that the flux between 1 and 24 hours was markedly reduced, demonstrating path closure. At 24 hours, all compounds and combinations significantly increased the PPS flux. The total amount of PPS transported is shown in FIG. 6. This result supports the conclusions presented in Example 4 and demonstrates that lower concentrations of anti-healing agents are also very effective at inhibiting microprojection pathway closure.
    [137] Example 6
    [138] To determine whether passive intradermal delivery of a plasmid DNA vaccine (pCMV-AYW-HBs-Mkan) encoding hepatitis B surface antigen [HBsAg] can be performed using Macroflux, alopecia guinea pig ( HGPs). In alopecia guinea pigs (HGPs), one side of the skin was pulled on both sides when using the system. The use of microprojection arrays was performed with the impact applicator. The system used consisted of a foam double adhesive ring (2.5 cm in diameter, 0.08 cm thick) with a 1 cm 2 reservoir roll in the center.
    [139] One of the two shaped microprojection arrays was used. The specific description of both arrays is shown in the table below. The total area of each shape is 2 cm 2 and the surface area of the entire active blade is 1 cm 2 .
    [140]
    [141] The microprojection array of the selected type was fixed to the adhesive foam and the bottom of the reservoir was covered (after use, the microprojection array is in contact with the skin). After use, the stretching tension was released and the microprojection array was left in place. The solution (90 μL) containing 3.5 mg / mL plasmid DNA vaccine in buffer (TRIS 5 mM pH 7.6) was dispersed into the drug compartment and the support membrane was used on the adhesive outer surface of the ring to seal the system. Additional HGPs were treated in the same manner, except that the formulation included 1% Tween 80 or 3% trisodium citrate salt in addition to plasmid DNA and Tris buffer. After 1 hour of use two systems were removed from each group and the remaining formulation was washed from the skin. The amount of drug penetrated at this time was measured on a 6 mm diameter complete layer skin biopsy taken from the skin site. Biopsies were dissolved in digestion buffer (sodium dodecyl sulfate / proteinase K) and PCR products were electrophoresed after polymerase chain reaction (PCR) to assess the relevant DNA content. Positive controls included those consisting of 10 μg plasmid DNA injected intradermal. The negative control consisted of plasmid DNA used for the skin without the use of microprojection arrays. The results demonstrated that the plasmid DNA can be successfully delivered using the microprojection array device during manual delivery (FIG. 7). Plasmid DNA could not be detected in the skin when using plasmid DNA without the microprojection array (negative control). Comparison between groups indicates that the most effective formulations include trisodium citrate salts. It was observed that the plasmid DNA delivered in the presence of trisodium citrate salt increased at least 10-fold when compared to the control formulation at 1 hour. There was no significant increase in plasmid DNA delivered in preparations containing Tween 80. Using the 21-10A microprojection array with citric acid resulted in a 2.5-fold increase in the amount of plasmid DNA delivered compared to the 8-1 A microprojection array, consistent with the number of overhangs in the 21-10A array.
    [142] Example 7
    [143] Examples 2-6 demonstrate that drugs of interest can increase flux by co-delivery of pathway closure inhibitors. In particular, compounds that exhibit anticoagulant properties have been shown to be effective in preventing pathway disruption. If these drugs prolong the delivery of drug molecules by preventing pathway disruption, they will prolong their delivery if they are highly enriched to deliver local anticoagulant action. Delivery tests with drugs exhibiting anticoagulant properties were conducted in HGP using PPS and phosphorothioated oligonucleotides ISIS 2302. PPS is a drug used in the treatment of inflammatory conditions such as interstitial cystitis and phosphorothioated oligonucleotide ISIS 2302 is an antisense drug for mRNA encoding the ICAM 1 molecule and exhibits anti-inflammatory properties. The two molecules are highly negatively charged compounds and do not significantly penetrate the skin without the use of penetration enhancers or physical destruction of the skin membrane.
    [144] 2 cm 2 manual pretreatment system, consistent with that described in Example 3, consisting of a stainless steel sheet with an area of 2 cm 2 and a thickness of 0.025 mm, with a trapezoidal blade bent at an angle of about 90 ° to the sheet surface. Microprotrusion length from 430 micrometer microprotrusion density using microprotrusions of 72 microprotrusions / cm 2 ) with a PPS at a concentration of 300 mg / mL, with a total amount of 6.5 ± 1.1 mg for 24 hours in HGP. Serve the picture. The amount released from urine (2 mg) was found to be more than 85% completely. This is in contrast to oral delivery of PPS, which shows a bioavailability of 1 to 3% (3 to 9 mg absorbed) of 300 mg daily. In addition, 1-5% of the absorbed delivery after oral delivery was completely found in urine, suggesting that transdermal delivery of PPS using microprojection arrays bypasses the liver.
    [145] Additional tests were conducted with PPS to test alternative modes of delivery. PPS with 50 mg / mL concentration, the total delivery amount of 1.9 ± 0.1 mg over 4 hours is electron transport of 100μA / cm 2 , and a stainless steel sheet with sheet area of 2 cm 2 and a thickness of 0.025 mm It was composed of a trapezoidal blade bent at an angle of about 90 °, and the microprojections were delivered by microprojections having a length of 430 micrometers and a density of 241 microprojections / cm 2 . In contrast, with the same microprojection array and the same PPS concentration, the total amounts of pretreatment with transdermal microprojection array and microprojection array with integrated drug reservoir and successive drug reservoirs were 2.2 ± 0.2 mg and 1.4 ± 0.2 mg, respectively. . Collectively, this result demonstrates that PPS can be effectively delivered over a long period of time, which may be a result of the anticoagulant properties of PPS.
    [146] Phosphorothioate oligonucleotide has a rate localized area of the oligonucleotide ISIS 2302 2cm 2 and a length of 480μm was delivered for 24 hours using 241 micro-projections / cm 2 of the fine protrusions. Drug concentrations, microprojection array pretreatment vs. integration and manual delivery versus electrotransportation were evaluated. The results summarized in Table III demonstrate that this compound can be effectively delivered through the skin for long periods of time, which may be a result of its anticoagulant properties.
    [147] TABLE III
    [148] ISIS 2302 Transdermal Delivery
    [149]
    [150] Drugs of interest that can be delivered without the aid of adjuvant to prevent path disruption at a therapeutic level using microprotrusion techniques for extended periods of time (ie 24 hours) exhibit anticoagulant properties upon local delivery and exceed about 2000 All compounds having a molecular weight are included. These compounds include hydrin analogs such as pentosan polysulfate, oligonucleotides, low molecular weight heparin, hirudin and hirlog.
    [151] Those skilled in the art will appreciate that the present invention may be embodied in other specific forms without departing from its spirit or its essence. Thus, the examples described herein are illustrative in all respects and are not intended to be limiting. It is intended that the appended claims rather than the foregoing description cover all modifications within the scope of this invention and its meaning and scope.
    权利要求:
    Claims (49)
    [1" claim-type="Currently amended] Destroying at least the stratum corneum of the skin to form a plurality of pathways;
    Causing the first drug and the at least one anti-healing drug to be fluxed through the route, wherein the amount of anti-healing drug fluxed through the route is such that the transdermal flux of the first drug is at least one anti-healing A method of inhibiting percutaneous flux reduction of a first drug that is effective to inhibit reduction relative to the flux of the first drug under substantially the same conditions except that no drug is present.
    [2" claim-type="Currently amended] The method of claim 1, wherein the skin breakage is a microslit caused by one or more keratin-perforated microprojections.
    [3" claim-type="Currently amended] The method of claim 1, wherein the anti-healing drug is selected from the group consisting of anticoagulants, anti-inflammatory agents, cell migration inhibitors, and osmotic agents and mixtures thereof.
    [4" claim-type="Currently amended] The group of claim 3 wherein the anticoagulant comprises heparin, pentosan polysulfate, citric acid, citrate salt, EDTA, and dextran, aspirin, and liafolate sodium having a molecular weight of 3000 to 12,000 daltons. Selected from.
    [5" claim-type="Currently amended] The method of claim 3, wherein the anti-inflammatory agent is hydrocortisone sodium phosphate, betamethasone sodium phosphate, and triamcinolone sodium phosphate.
    [6" claim-type="Currently amended] The method of claim 3, wherein the cell migration inhibitor is laminin.
    [7" claim-type="Currently amended] The method of claim 3, wherein the osmotic agent is a biocompatible salt of the osmotic agent.
    [8" claim-type="Currently amended] The method of claim 3, wherein the osmotic agent in solution produces an osmotic pressure greater than about 2000 kilopascals at 20 ° C. 5.
    [9" claim-type="Currently amended] The method of claim 1, wherein the first drug is a therapeutic agent that is transdermally delivered to the skin.
    [10" claim-type="Currently amended] The method of claim 9, wherein the drug comprises a macromolecular drug.
    [11" claim-type="Currently amended] The method of claim 10, wherein the macromolecular drug is selected from the group consisting of polypeptides, proteins, oligonucleotides, nucleic acids, and polysaccharides.
    [12" claim-type="Currently amended] The method of claim 9, wherein the disruption is one or more microslits through the stratum corneum that forms the pathway; And positioning the reservoir containing the first drug and the anti-healing drug in a drug delivery relationship with the microslit.
    [13" claim-type="Currently amended] The method of claim 1, wherein the first drug is a body assay sample that is percutaneously sampled.
    [14" claim-type="Currently amended] The method of claim 13, wherein the analytical sample is glucose.
    [15" claim-type="Currently amended] The method of claim 13, wherein the disruption is one or more microslits through the stratum corneum that forms the pathway; And positioning the reservoir containing the first drug in drug delivery relationship with the microslit.
    [16" claim-type="Currently amended] The method of claim 1, wherein the anti-healing drug is
    (a) prior to transdermal flux of the first drug;
    (b) before and during the transdermal flux of the first drug;
    (c) during transdermal plus of the first drug; or
    (d) Delivery during and after transdermal flux of the first drug.
    [17" claim-type="Currently amended] The method of claim 2, wherein the microprojection length is less than 0.5 mm.
    [18" claim-type="Currently amended] The method of claim 15, wherein the microprojections and the reservoir are part of a single sampling device.
    [19" claim-type="Currently amended] The method of claim 1, wherein the first drug is selected from the group consisting of heparin, pentosan polysulfate, citric acid, citrate salt, EDTA, and dextran having a molecular weight of 2000 to 10,000 daltons.
    [20" claim-type="Currently amended] The method of claim 19, wherein the first drug is the same as at least one anti-healing drug.
    [21" claim-type="Currently amended] The method of claim 3, wherein the osmotic agent is a neutral compound.
    [22" claim-type="Currently amended] The method of claim 2, wherein the first drug and the anti-healing drug are dry-coated on one or more microprojections.
    [23" claim-type="Currently amended] The method of claim 2, wherein the first drug is a therapeutic agent coated on the microprojection and the first drug is transdermally delivered to the skin.
    [24" claim-type="Currently amended] The method of claim 23, further comprising localizing a separate reservoir comprising an anti-healing drug in a drug delivery relationship with the skin.
    [25" claim-type="Currently amended] A first element capable of disrupting at least the stratum corneum of the skin to form a path therethrough;
    At least one reservoir comprising a first drug and at least one anti-healing drug, which may be in a drug delivery relationship with the skin and the route, wherein the amount of the at least one anti-healing drug is a transdermal flux of the first drug Is effective to inhibit a decrease compared to the flux of the first drug under substantially the same conditions except that there is no at least one anti-healing drug.
    [26" claim-type="Currently amended] The device of claim 25, wherein the first element comprises one or more keratin-perforated microprojections that can form microslits in the skin.
    [27" claim-type="Currently amended] The device of claim 25, wherein the anti-healing drug is selected from the group consisting of anticoagulants, anti-inflammatory agents, cell migration inhibitors, and osmotic agents and mixtures thereof.
    [28" claim-type="Currently amended] The group of claim 27 wherein the anticoagulant comprises heparin, pentosan polysulfate, citric acid, citrate salt, EDTA, and dextran, aspirin, and liafolate sodium having a molecular weight of 2000 to 10,000 daltons. Device selected from.
    [29" claim-type="Currently amended] The device of claim 27, wherein the anti-inflammatory agent is hydrocortisone sodium phosphate, betamethasone sodium phosphate, and triamcinolone sodium phosphate.
    [30" claim-type="Currently amended] The device of claim 27, wherein the cell migration inhibitor is laminin.
    [31" claim-type="Currently amended] The device of claim 27, wherein the osmotic agent is a biocompatible salt of the osmotic agent.
    [32" claim-type="Currently amended] The apparatus of claim 27, wherein the osmotic agent in solution produces an osmotic pressure greater than about 2000 kilopascals at 20 ° C. 29.
    [33" claim-type="Currently amended] The device of claim 25, wherein the first drug is a therapeutic agent and transdermally delivers the first drug to the skin.
    [34" claim-type="Currently amended] The device of claim 33, wherein the drug comprises a macromolecular drug.
    [35" claim-type="Currently amended] 35. The device of claim 34, wherein the macromolecular drug is selected from the group consisting of polypeptides, proteins, oligonucleotides, nucleic acids, and polysaccharides.
    [36" claim-type="Currently amended] 34. The device of claim 33, wherein the first element comprises one or more keratin-perforated microprojections that can destroy the skin by forming microslits in the skin.
    [37" claim-type="Currently amended] The device of claim 25, wherein the first drug is a body assay sample that is percutaneously sampled.
    [38" claim-type="Currently amended] 38. The device of claim 37, wherein the analytical sample is glucose.
    [39" claim-type="Currently amended] 38. The device of claim 37, wherein the first element comprises one or more keratin-perforated microprojections that can form microslits in the skin and destroy the skin.
    [40" claim-type="Currently amended] The method of claim 25, wherein the anti-healing drug is
    (a) prior to transdermal flux of the first drug;
    (b) before and during the transdermal flux of the first drug;
    (c) during transdermal plus of the first drug; or
    (d) A device for delivering during and after transdermal flux of the first drug.
    [41" claim-type="Currently amended] 27. The device of claim 26, wherein the microprojection length is less than 0.5 mm.
    [42" claim-type="Currently amended] 40. The device of claim 39, wherein the microprojections and the reservoir are integral elements.
    [43" claim-type="Currently amended] The device of claim 25, wherein the first drug is selected from the group consisting of heparin, pentosan polysulfate, citric acid, citrate salt, EDTA, and dextran having a molecular weight of 2000 to 10,000 daltons.
    [44" claim-type="Currently amended] The device of claim 43, wherein the first drug is the same as the at least one anti-healing drug.
    [45" claim-type="Currently amended] The device of claim 27, wherein the osmotic agent is a neutral compound.
    [46" claim-type="Currently amended] 27. The device of claim 26, wherein the first drug and the anti-healing drug are dry-coated on one or more microprojections.
    [47" claim-type="Currently amended] 27. The device of claim 26, wherein the first drug is a therapeutic agent coated on the microprojection and the transdermal delivery of the first drug to the skin.
    [48" claim-type="Currently amended] 48. The device of claim 47, further comprising localizing a separate reservoir comprising an anti-healing drug in a drug delivery relationship with the skin.
    [49" claim-type="Currently amended] The apparatus of claim 1 and
    Apparatus for applying the first element of the device on the skin for destruction:
    Kit for applying the transdermal flux inducing device of the drug comprising a.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP6068761B2|2017-01-25|Permeate delivery system and method of use
    JP6692761B2|2020-05-13|Permeate delivery system and method of use thereof
    CN104080441B|2020-02-28|Microneedle devices comprising peptide therapeutics and amino acids, methods of making and using the same
    RU2711567C2|2020-01-17|Microchip for drug delivery and methods for use thereof
    CA2315469C|2009-04-21|Method and apparatus for the transdermal administration of a substance
    US6918901B1|2005-07-19|Device and method for enhancing transdermal agent flux
    DE60105813T2|2005-11-17|Vaccine-coated needles
    EP1844763B1|2018-08-08|Percutaneously absorbable preparation, percutaneously absorbable preparation holding sheet, and percutaneously absorbable preparation holding equipment
    US5947921A|1999-09-07|Chemical and physical enhancers and ultrasound for transdermal drug delivery
    Cross et al.2004|Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development?
    KR930005319B1|1993-06-17|Method and composition for coiontophoresis
    KR100993477B1|2010-11-11|Rapidly dissolving micro-perforator for drug delivery and other applications
    CN1842320B|2013-06-19|Formulations for coated microprojections containing non-volatile counterions
    CA2410561C|2009-05-12|Applicator having abrading surface coated with substance to be applied to skin
    US6855372B2|2005-02-15|Method and apparatus for coating skin piercing microprojections
    Brown et al.2008|Transdermal drug delivery systems: skin perturbation devices
    A Charoo et al.2010|Electroporation: an avenue for transdermal drug delivery
    EP1439870B1|2009-01-14|Device for the delivery of a substance
    KR100832754B1|2008-05-27|Skin treatment apparatus for sustained transdermal drug delivery
    DE60122723T2|2007-09-20|Device for transdermal delivery and administration of a substance to the patient
    JP4917540B2|2012-04-18|Method and apparatus for supplying a substance containing a coating
    KR100870345B1|2008-11-25|Needle for intradermal delivery of substances having penetration limiting means
    US7182747B2|2007-02-27|Solid solution perforator for drug delivery and other applications
    US5814599A|1998-09-29|Transdermal delivery of encapsulated drugs
    JP2011172968A|2011-09-08|Microprojection array having beneficial agent containing coating
    同族专利:
    公开号 | 公开日
    NO20031071D0|2003-03-07|
    NO20031071L|2003-05-06|
    CA2422200A1|2002-03-14|
    JP5507030B2|2014-05-28|
    AU8877401A|2002-03-22|
    RU2272618C2|2006-03-27|
    ZA200302700B|2004-08-13|
    US7438926B2|2008-10-21|
    KR100764699B1|2007-10-08|
    EP1335711A2|2003-08-20|
    PT1335711E|2007-09-05|
    DE60129585D1|2007-09-06|
    CN100421653C|2008-10-01|
    US20020102292A1|2002-08-01|
    WO2002019985A2|2002-03-14|
    ES2290166T3|2008-02-16|
    NZ524646A|2004-10-29|
    CN1473037A|2004-02-04|
    EE200300095A|2005-02-15|
    MA25958A1|2003-12-31|
    CZ2003687A3|2004-01-14|
    IL154811D0|2003-10-31|
    DK1335711T3|2007-11-26|
    JP2004508319A|2004-03-18|
    BR0113749A|2004-06-22|
    MXPA03002122A|2004-09-10|
    WO2002019985A3|2002-09-06|
    EP1335711B1|2007-07-25|
    PL365603A1|2005-01-10|
    DE60129585T2|2008-04-17|
    AU2001288774B2|2006-06-29|
    AT367805T|2007-08-15|
    JP2013256500A|2013-12-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2000-09-08|Priority to US23116000P
    2000-09-08|Priority to US60/231,160
    2001-09-06|Application filed by 알자 코포레이션
    2001-09-06|Priority to PCT/US2001/027551
    2003-09-19|Publication of KR20030074595A
    2007-10-08|Application granted
    2007-10-08|Publication of KR100764699B1
    优先权:
    申请号 | 申请日 | 专利标题
    US23116000P| true| 2000-09-08|2000-09-08|
    US60/231,160|2000-09-08|
    PCT/US2001/027551|WO2002019985A2|2000-09-08|2001-09-06|Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure|
    [返回顶部]